Basic information Safety Supplier Related

Dalotuzumab

Basic information Safety Supplier Related

Dalotuzumab Basic information

Product Name:
Dalotuzumab
Synonyms:
  • Dalotuzumab
  • Research Grade Dalotuzumab(DHC29901)
  • Research Grade Dalotuzumab
  • Dalotuzumab (anti-IGF1R)
CAS:
1005389-60-5
MW:
0
Mol File:
Mol File
More
Less

Dalotuzumab Chemical Properties

form 
Liquid
color 
Colorless to light yellow
More
Less

Dalotuzumab Usage And Synthesis

Uses

Dalotuzumab (MK-0646) is a recombinant humanized monoclonal antibody (IgG1 type) targeting IGF-1R. Dalotuzumab acts by inhibiting IGF-1- and IGF-2-mediated tumor cell proliferation, IGF-1R autophosphorylation, and Akt phosphorylation. Dalotuzumab also induces apoptosis and cycle arrest. Dalotuzumab in combination with other anticancer agents such as statins can enhance the antitumor activity of Dalotuzumab in vitro and in vivo[1][2][3].

in vivo

Dalotuzumab (h7C10; i.p.; 250 μg/mice for the first time, then 125 μg/mice twice weekly for 40 days) shows anti-tumor effects on MCF-7 and A549 xenograft tumor models[1].

Animal Model:Swiss Nude mice (MCF-7 and A549 xenograft tumor models)[1].
Dosage:125 and 250 (first time) μg/mice
Administration:Intraperitoneal injection; 250 μg/mice for the first time, then 125 μg/mice twice weekly for 40 days
Result:Led to average tumor volume at 6 weeks post-cell injection was reduced by 70% and 72% in the MCF-7 and A549 models, respectively.

References

[1] Goetsch L, et al. A recombinant humanized anti-insulin-like growth factor receptor type I antibody (h7C10) enhances the antitumor activity of vinorelbine and anti-epidermal growth factor receptor therapy against human cancer xenografts. Int J Cancer. 2005 Jan 10;113(2):316-28. DOI:10.1002/ijc.20543
[2] Bitelman C, et al. IGF1R-directed targeted therapy enhances the cytotoxic effect of chemotherapy in endometrial cancer. Cancer Lett. 2013 Jul 10;335(1):153-9. DOI:10.1016/j.canlet.2013.02.009
[3] Scartozzi M, et al. Dalotuzumab, a recombinant humanized mAb targeted against IGFR1 for the treatment of cancer. Curr Opin Mol Ther. 2010 Jun;12(3):361-71. PMID:20521225

DalotuzumabSupplier

Shanghai YuanYe Biotechnology Co., Ltd.
Tel
021-61312847; 18021002903
Email
3008007409@qq.com
ShangHai Biochempartner Co.,Ltd
Tel
177-54423994 17754423994
Email
2853530910@QQ.com
Guangzhou Hongyuan Chemical Co.,Ltd
Tel
15817493340
Email
981810490@qq.com
Wuhan Chemstan Biotechnology Co., Ltd.
Tel
027-65317797 15926423062
Email
422450190@qq.com
Biolab Reagents
Tel
027-65279366 18108604356
Email
products@biolabreagent.com
More
Less